Skip to main content

Table 2 Correlation between GAB2/CRKL/FRS2 expression and clinicopathological characteristics of PDCA

From: Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma

Parameter

GAB2 n (%)

P

CRKL n (%)

P

FRS2 n (%)

P

GAB2/CRKL/FRS2 n (%)

P

Negative

Positive

Negative

Positive

Negative

Positive

Negativea

Positiveb

Sex

  

1.000

  

1.000

  

1.000

  

0.762

 Female

22(61.1%)

14(38.9%)

17(47.2%)

19(52.8%)

23(63.9%)

13(36.1%)

29(80.6%)

7(19.4%)

 Male

23(59.0%)

16(41.0%)

18(45.0%)

22(55.0%)

27(65.9%)

14(34.1%)

35(85.4%)

6(14.6%)

Age at diagnosis

  

1.000

  

0.645

  

0.811

  

1.000

  ≤ 60

21(60.0%)

14(40.0%)

18(50.0%)

18(50.0%)

25(67.6%)

12(32.4%)

31(83.6%)

6(16.2%)

  > 60

24(60.0%)

16(40.0%)

17(42.5%)

23(57.5%)

25(62.5%)

15(37.5%)

33(82.5%)

7(17.5%)

Size (diameter),

  

0.255

  

0.260

  

0.557

  

0.452

  ≤ 2 cm

7(46.7%)

8(53.3%)

5(31.3%)

11(68.7%)

9(56.3%)

7(43.8%)

12(75.0%)

4(25.0%)

  > 2 cm

38(63.3%)

22(36.7%)

30(50.0%)

30(50.0%)

41(67.2%)

20(32.8%)

52(85.2%)

9(14.8%)

Tumor sites

  

0.246

  

0.645

  

0.161

  

0.367

 Head

26(66.7%)

13(33.3%)

17(42.5%)

23(57.5%)

29(72.5%)

11(27.5%)

35(87.5%)

5(12.5%)

 Body/Tail

19(52.8%)

17(47.2%)

18(50.0%)

18(50.0%)

21(56.8%)

16(43.2%)

29(78.4%)

8(21.6%)

Resection margins

  

1.000

  

1.000

  

1.000

  

1.000

 Negative

37(59.7%)

25(40.3%)

29(46.0%)

34(54.0%)

41(64.1%)

23(35.9%)

53(82.8%)

11(17.2%)

 Positive

8(61.5%)

5(38.5%)

6(46.2%)

7(53.8%)

9(69.2%)

4(30.8%)

11(84.6%)

2(15.4%)

Differentiation

  

1.000

  

0.187

  

0.581

  

0.288

 Well/moderate

34(60.7%)

22(39.3%)

29(50.9%)

28(49.1%)

39(67.2%)

19(32.8%)

50(86.2%)

8(13.8%)

 Poor

11(57.9%)

8(42.1%)

6(31.6%)

13(68.4%)

11(57.9%)

8(42.1%)

14(73.7%)

5(26.3%)

Nodal metastasis

  

0.640

  

0.642

  

0.337

  

0.122

 No

17(56.7%)

13(43.3%)

13(41.9%)

18(58.1%)

18(58.1%)

13(41.9%)

23(74.2%)

8(25.8%)

 Yes

28(62.2%)

17(37.8%)

22(48.9%)

23(51.5%)

32(69.6%)

14(30.4%)

41(89.1%)

5(10.9%)

TNM stage

  

1.000

  

1.000

  

1.000

  

1.000

 I/II

38(60.3%)

25(39.7%)

30(46.2%)

35(53.8%)

42(64.6%)

23(35.4%)

54(83.1%)

11(16.9%)

 III/IV

7(58.3%)

5(41.7%)

5(45.5%)

6(54.5%)

8(66.7%)

4(33.3%)

10(83.3%)

2(16.7%)

  1. aNegative indicates that one or two of the indexes: GAB2, CRKL, and FRS2 are positive. The three torn-off specimens happened to be from tumors that are negative for one or two of the three proteins and are thus categorized into the GAB2/CRKL/FRS2 negative group despite not knowing the actual expression of one or two of the adaptor proteins
  2. bPositive indicates all indexes positive of GAB2,CRKL and FRS2